Fortrea Holdings Inc. (FTRE) AI Stock Analysis

• Market Cap: $717.32M
• Dividend Yield: N/A
• Average Volume (3M): 1.93M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -4.96%
• EPS Growth: -284.00%
• Country: US
• Employees: 15,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.19
• Shares Outstanding: 90,800,000
• 10 Day Avg. Volume: 2,136,111
• 30 Day Avg. Volume: 1,926,216
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.24
• Enterprise Value/Revenue: 0.59
• Enterprise Value/Gross Profit: 3.09
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $6.75
• Price Target Upside: -16.04% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 10

• Rating: 59 Neutral
• Price Target: $8.00 ▼(-0.50% Downside)

Fortrea Holdings Inc. faces significant financial challenges, particularly in profitability and cash flow management, which heavily impact its overall score. Despite positive technical indicators and some operational improvements highlighted in the earnings call, the negative valuation metrics and financial struggles weigh down the stock's attractiveness.

Positive Factors

Earnings Performance

The company's revenue, adjusted EBITDA, and adjusted EPS were better than expected, along with a 6% raise to the midpoint of the company’s 2025 revenue guide.

Executive Leadership

Fortrea was up over 5% in after-hours trading on the back of its new CEO announcement.

Strategic Initiatives

The company continues to make progress with its transformation efforts, achieving one-third of its $90 million-$100 million net savings target for 2025 in the first half of the year.

Negative Factors

Bookings and Revenue Guidance

Net new business awards of $561 million were significantly below the estimate of $719 million.

Market Conditions

The biotech and large pharma markets continue to show softness, which influences Fortrea Holdings negatively.

Operational Challenges

The company could continue to lose share because of execution issues and spin-related disruptions.

Fortrea Holdings Inc. Business Overview & Revenue Model

Company Description

Fortrea Holdings Inc. (FTRE) operates in the healthcare sector, focusing on providing clinical trial solutions and laboratory services to pharmaceutical, biotechnology, and medical device companies. The company supports its clients in the development and approval of new medical treatments by offering comprehensive end-to-end clinical trial management services and advanced laboratory testing capabilities.

How the Company Makes Money

Fortrea Holdings Inc. generates revenue primarily through its clinical trial management and laboratory services. The company earns income by offering a suite of services that include clinical trial design, patient recruitment, data management, and regulatory compliance support. Additionally, Fortrea provides laboratory testing services that assist in the drug development process. Revenue streams are bolstered by long-term contracts with pharmaceutical and biotechnology companies, as well as partnerships with medical institutions seeking to advance their research and development efforts. The company's earnings are significantly influenced by trends in the healthcare and pharmaceutical industries, particularly the demand for new drug development and approval.

Fortrea Holdings Inc. Financial Statement Overview

Summary

Fortrea Holdings Inc. faces financial challenges with declining revenue and profitability, negative margins, and net losses. The balance sheet shows high leverage, posing potential risks, while cash flow management demonstrates some resilience with positive operating cash flow.

Income Statement

The income statement shows declining revenue and profitability over recent periods, with a significant net loss in the TTM period. Revenue decreased from previous periods, and the company has negative EBIT and EBITDA margins, indicating operational challenges and inefficiencies.

Balance Sheet

The balance sheet reflects a relatively high debt-to-equity ratio due to substantial debt levels, which could pose financial risks. Although stockholders' equity has decreased over time, the company maintains a reasonable equity ratio, indicating some stability in asset financing.

Cash Flow

Cash flow analysis indicates a decline in free cash flow compared to previous periods, yet the company maintains a positive operating cash flow. The free cash flow to net income ratio suggests some cash flow management strengths, although overall growth in free cash flow is limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.73B	2.70B	2.84B	3.10B	3.06B
Gross Profit	519.60M	534.20M	590.60M	621.70M	604.40M
EBITDA	-858.80M	-64.30M	137.20M	354.60M	335.20M
Net Income	-1.03B	-328.50M	-25.20M	192.90M	98.00M
Balance Sheet
Total Assets	2.84B	3.58B	4.33B	4.29B	4.37B
Cash, Cash Equivalents and Short-Term Investments	81.20M	118.50M	108.60M	112.00M	94.60M
Total Debt	1.24B	1.20B	1.67B	63.40M	77.20M
Total Liabilities	2.25B	2.22B	2.62B	945.30M	1.11B
Stockholders Equity	589.20M	1.36B	1.71B	3.34B	3.26B
Cash Flow
Free Cash Flow	-103.10M	237.30M	127.10M	33.10M	143.30M
Operating Cash Flow	-87.70M	262.80M	167.40M	87.50M	169.80M
Investing Cash Flow	4.00M	251.60M	-31.80M	-54.00M	-26.20M
Financing Cash Flow	34.30M	-497.80M	-140.80M	-8.70M	-128.50M

Fortrea Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTRE, the sentiment is Positive. The current price of 8.04 is above the 20-day moving average (MA) of 6.58, above the 50-day MA of 5.76, and below the 200-day MA of 11.34, indicating a neutral trend. The MACD of 0.60 indicates Negative momentum. The RSI at 67.66 is Neutral, neither overbought nor oversold. The STOCH value of 94.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTRE.

Fortrea Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FULC	60 Neutral	$357.00M	―	-30.00%	―	-100.00%	-266.37%
CMPX	60 Neutral	$407.93M	―	-51.84%	―	-100.00%	-25.75%
FTRE	59 Neutral	$717.32M	―	-100.49%	―	-4.96%	-284.00%
NKTR	56 Neutral	$507.61M	―	-440.80%	―	-19.56%	35.55%
Sector *	54 Neutral	€4.19B	12.94	-41.26%	2.53%	14.43%	-26.74%
AURA	43 Neutral	$434.84M	―	-55.39%	―	―	-9.14%
ERAS	34 Underperform	$445.36M	―	-31.16%	―	―	50.77%

Fortrea Holdings Inc. Corporate Events

Fortrea Holdings Approves Key Proposals at Annual Meeting

On June 10, 2025, Fortrea Holdings Inc. held its Annual Meeting of Stockholders where several key proposals were approved. The amendment and restatement of the 2023 Omnibus Incentive Plan was a significant highlight, increasing the number of shares by 6,500,000 and introducing new vesting and dividend conditions. Additionally, the election of directors, ratification of Deloitte & Touche LLP as the independent auditor, and the advisory vote on executive compensation were also approved.

The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.

Fortrea Holdings Inc. Adopts Stockholder Rights Plan

On June 11, 2025, Fortrea Holdings Inc. announced the adoption of a limited-duration stockholder rights plan, effective immediately, to protect the interests of its stockholders amidst significant dislocation in its stock trading price. The plan, which expires on June 10, 2026, aims to ensure fair treatment in takeover scenarios and prevent hostile acquisitions without appropriate premiums. It allows stockholders to purchase additional shares at a discount if any entity acquires 10% or more of Fortrea’s common stock, encouraging potential acquirers to engage directly with the Board.

The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.

Fortrea Holdings Appoints Anshul Thakral as New CEO

On June 11, 2025, Fortrea Holdings Inc. announced the appointment of Anshul Thakral as the new President and CEO, effective August 4, 2025, succeeding interim CEO Peter M. Neupert, who will remain as chairman of the board. Thakral, with over 20 years of experience in the life sciences sector, aims to focus on executing Fortrea’s transformation plan and enhancing its focus on profitable growth, while overseeing efforts to create additional value for customers, employees, and shareholders.

The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.